Why should we need the gut microbiota to respond to cancer therapies?

Cyclophosphamide, one of the most efficient tumoricidal, antiangiogenic, and immunostimulatory drugs employed to date mediates part of its effects through intestinal bacteria, against which the host becomes immunized during treatment. Our recent work suggests that anti-commensal effector pT(H)17 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Viaud, Sophie, Daillère, Romain, Yamazaki, Takahiro, Lepage, Patricia, Boneca, Ivo, Goldszmid, Romina, Trinchieri, Giorgio, Zitvogel, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006853/
https://www.ncbi.nlm.nih.gov/pubmed/24800167
http://dx.doi.org/10.4161/onci.27574
_version_ 1782314274624897024
author Viaud, Sophie
Daillère, Romain
Yamazaki, Takahiro
Lepage, Patricia
Boneca, Ivo
Goldszmid, Romina
Trinchieri, Giorgio
Zitvogel, Laurence
author_facet Viaud, Sophie
Daillère, Romain
Yamazaki, Takahiro
Lepage, Patricia
Boneca, Ivo
Goldszmid, Romina
Trinchieri, Giorgio
Zitvogel, Laurence
author_sort Viaud, Sophie
collection PubMed
description Cyclophosphamide, one of the most efficient tumoricidal, antiangiogenic, and immunostimulatory drugs employed to date mediates part of its effects through intestinal bacteria, against which the host becomes immunized during treatment. Our recent work suggests that anti-commensal effector pT(H)17 and memory T(H)1 CD4(+) T-cell responses are indispensable for optimal anticancer effects as mediated by cyclophosphamide.
format Online
Article
Text
id pubmed-4006853
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40068532015-01-17 Why should we need the gut microbiota to respond to cancer therapies? Viaud, Sophie Daillère, Romain Yamazaki, Takahiro Lepage, Patricia Boneca, Ivo Goldszmid, Romina Trinchieri, Giorgio Zitvogel, Laurence Oncoimmunology Author's View Cyclophosphamide, one of the most efficient tumoricidal, antiangiogenic, and immunostimulatory drugs employed to date mediates part of its effects through intestinal bacteria, against which the host becomes immunized during treatment. Our recent work suggests that anti-commensal effector pT(H)17 and memory T(H)1 CD4(+) T-cell responses are indispensable for optimal anticancer effects as mediated by cyclophosphamide. Landes Bioscience 2014-01-17 /pmc/articles/PMC4006853/ /pubmed/24800167 http://dx.doi.org/10.4161/onci.27574 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Viaud, Sophie
Daillère, Romain
Yamazaki, Takahiro
Lepage, Patricia
Boneca, Ivo
Goldszmid, Romina
Trinchieri, Giorgio
Zitvogel, Laurence
Why should we need the gut microbiota to respond to cancer therapies?
title Why should we need the gut microbiota to respond to cancer therapies?
title_full Why should we need the gut microbiota to respond to cancer therapies?
title_fullStr Why should we need the gut microbiota to respond to cancer therapies?
title_full_unstemmed Why should we need the gut microbiota to respond to cancer therapies?
title_short Why should we need the gut microbiota to respond to cancer therapies?
title_sort why should we need the gut microbiota to respond to cancer therapies?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006853/
https://www.ncbi.nlm.nih.gov/pubmed/24800167
http://dx.doi.org/10.4161/onci.27574
work_keys_str_mv AT viaudsophie whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT daillereromain whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT yamazakitakahiro whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT lepagepatricia whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT bonecaivo whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT goldszmidromina whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT trinchierigiorgio whyshouldweneedthegutmicrobiotatorespondtocancertherapies
AT zitvogellaurence whyshouldweneedthegutmicrobiotatorespondtocancertherapies

Ejemplares similares